The milestone is based on Genentech’s continued progress in preclinical development with an antibody-drug conjugate (ADC) utilizing Seattle Genetics’ technology.
“We believe our ADC technology is contributing significantly to advancing the field of antibody-based therapeutics,” stated Dr Clay Siegall, president and CEO of Seattle Genetics. “We are pleased that Genentech is utilizing our ADC technology, and we look forward to continued collaboration towards developing a variety of targeted therapies.”
Seattle Genetics’ second-generation ADC technology utilizes the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells. The technology employs synthetic, highly potent drugs that can be attached to antibodies through proprietary linker systems. By linking drug payloads to monoclonal antibodies, ADCs can increase the cell-killing activity of antibodies that have inherent cell targeting ability.